Person: ÇELEBİ, SOLMAZ
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ÇELEBİ
First Name
SOLMAZ
Name
80 results
Search Results
Now showing 1 - 10 of 80
Publication A patient with breast mass and hyperemia(Aves Yayıncılık, 2007-06-01) Aktürk, Berna; Çelebi, Solmaz; Aktürk, Berna; ÇELEBİ, SOLMAZ; Tıp Fakültesi; Çocuk Sağlıkları ve Hastalıkları Ana Bilim Dalı; Çocuk Enfeksiyon Hastalıkları Bilim; CAS-1783-2022; JOA-9028-2023Publication Evaluation of children with ralstonia pickkettii Bacteraemia(Aves Yayıncılık, 2023-03-01) Yeşil, Edanur; Hacımustafaoğlu, Mustafa; Çelebi, Solmaz; Özer, Arife; Kilimci, Duygu Düzcan; Eren, Hale; Özakın, Cüneyt; HACIMUSTAFAOĞLU, MUSTAFA KEMAL; ÇELEBİ, SOLMAZ; Eren, Hale; ÖZAKIN, CÜNEYT; Tıp Fakültesi; Çocuk Enfeksiyon Hastalıkları Bilim Dalı; CTG-5805-2022; JHN-1091-2023; GQT-6881-2022; JKC-3728-2023Objective: Ralstonia pickettii is an opportunistic pathogen that is often considered to be contaminant. It can cause infection due to colonisation in infusion solutions and disinfectants. Although rare, it can lead to nosocomial outbreaks, so this agent should not be ignored. In this study, it was aimed to evaluate the growth of R. pickettii in blood cultures taken in the pediatric wards of our hospital, to analyze the outbreaks by R. pickettii and to discuss the precautions to prevent the outbreaks.Material and Methods: Patients with Ralstonia picketti in blood cultures, who were admitted in the pediatric intensive care unit (PICU; n= 46, 81%), neonatal intensive care unit (n= 7, 12%) and other pediatric wards (n= 4, 7%) between February 2014 and December 2017 were included into the study. Patient's data, the relation between the outbreaks and culture growths, and the sources and the prevention of potential outbreaks were evaluated. Recurrent growths were defined as a single episode.Results: Ralstonia pickettii detected in 57 different specimens in 38 different episodes in a total of 35 patients. Of the fifty-seven blood samples, 67% (n= 38) were peripheral blood cultures, 33% (n= 19) were catheter blood cultures and 74% of the samples lead to infection. Of the 38 ep-isodes, 63% (n= 24) were considered as infection and 37% (n= 14) was contamination. Median age of the patients were seven (0-180) months, and the major underlying comorbidity was congenital heart disease. Of 57 specimens with Raltstonia pickettii growth, 16 (28%) had only R. pickettii growth, and the remaining 41 (71%) cultured growths were poly -microbial. Among these, the most common accompanying microorganisms were Stenotrophomonas maltophilia and Burkholderia species. Of 38 episodes, 58% (n= 22) had a central venous catheter (CVC), of which 64% (n= 14) developed catheter-related bloodstream infection due to R. pickettii. Eighty-one percent of the specimens were detected in the pediatric in-tensive care unit, and the outbreak situation was examined. Twenty-three (61%) of a total of 57 growths were associated with an outbreak of health-care-associated infection in three separate periods. Ralstonia pickettii was not detected in environment scans. Antibiogram features of the growths were similar and they were thought to be of the same isolate, no molecular study was applied. Three patients died within the first 30 days after the growth.Conclusion: Our study has the largest case series reported in a pediatric population in Turkiye and the world. The mortality rate due to R. pickettii was low. Eighty-one percent of the specimens were in the pediatric inten-sive care unit and 61% was associated with the outbreak. The importance of hospital infection control measures in preventing R. pickettii and similar outbreaks were emphasized. A limited number of studies have been conducted on this subject in Turkiye, and we believe that our study will contribute to the literature.Publication Recurrent pneumonia in children(Aves Yayincilik, Ibrahim Kara, 2010-06-01) Çelebi, Solmaz; ÇELEBİ, SOLMAZ; Hacımustafaoğlu, Mustafa; HACIMUSTAFAOĞLU, MUSTAFA KEMAL; Albayrak, Yücehan; Bulur, Nurcan; Tıp Fakültesi; Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı; 0000-0003-4646-660XObjective: The aim of this study was to determine the relative frequency and describe the predisposing causes of recurrent pneumonia in children.Material and methods: We retrospectively reviewed the medical records of patients with pneumonia at Uludag University Medical Faculty, Department of Pediatrics, between January 1998 and December 2007. Recurrent pneumonia was defined as at least two episodes in a 1 year period or at least three episodes over a lifetime. Patients with recurrent pneumonia were included in this study.Results: During the study period, 1617 children were admitted to hospital with a diagnosis of pneumonia, 185 (11.4%) met the criteria for recurrent pneumonia. The mean age of patients was 16 +/- 32 months (3 months-14 years) and 61% were male. An underlying cause was identified in 143 patients (77%). Of these, the underlying cause was diagnosed prior the pneumonia in 25 patients (17%), during the first episode in 30 (21%), and during recurrence in 88 (62%). Underlying causes included congenital cardiac defects in 32 patients (17.2%), gastroesophageal reflux in 31 patients (16.7%), aspiration syndrome in 27 patients (14.5%), asthma in 16 patients (8.6%), cystic fibrosis in 12 patients (6.4%) immune disorders in 10 patients (5.4%), tuberculosis in 9 patients (4.8%) and anomalies of the chest and lung in 6 patients (3.2%). No predisposing illness could be demonstrated in 42 patients (33%).Conclusion: Recurrent pneumonia occurred in 11.4% of all children hospitalized for pneumonia. The underlying cause was identified in 77% of the children. The most common causes were congenital cardiac defects, gastroesophageal reflux and aspiration syndrome.Publication Comparison of c-reactive protein, procalcitonin and serum amyloid-a levels in diagnosis of bacterial infection in children(Aves Yayincilik, Ibrahim Kara, 2013-12-01) Çelebi, Solmaz; ÇELEBİ, SOLMAZ; ÖZAKIN, CÜNEYT; Bulur, Nurcan; Hacımustafaoğlu, Mustafa; HACIMUSTAFAOĞLU, MUSTAFA KEMAL; Özakın, Cüneyt; Çakır, Deniz; Bozdemir, Şefika Elmas; Çetin, Benhur Şirvan; Tıp Fakültesi; Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı; 0000-0003-4646-660X; 0000-0002-7056-0615; 0000-0002-8470-4907; GQP-2135-2022; AAG-8392-2021; H-2691-2017Objective: The aim of the study was to compare C-reactive protein (CRP), procalcitonin (PCT) and serum amyloid A (SAA) levels in children with bacterial infection.Material and Methods: In this prospective study, 120 pediatric patients who were hospitalized with bacterial infection in the Uludag University Medical Faculty Pediatric Clinic between June 2009 and June 2011 were included. Patients were evaluated in 5 groups as sepsis, pneumonia, meningitis, pyelonephritis and other infection groups. Before initiating the antimicrobial therapy, blood samples for whole blood count, blood culture, CRP, PCT and SAA were obtained from children with bacterial infection. This procedure was repeated three times at 48 h, 7 and 10 days. Whole blood count was performed using an automated counter, Cell Dyn 3700 (Abbott Diagnostics Division, Santa Clara, CA, USA). CRP and SAA were determined by an immunonephelometric method using BN II device (Dade Behring Marburg GMBH, Marburg, Germany). PCT was measured by EnzymeLinked Fluorescent Assay (VIDAS PCT; Brahm Diagnostica GMBH, Lyon, France).Results: Of the patients, 66 (55%) were male and 54 (45%) were female. The median age was 37.5 months (1-209). PCT levels of the sepsis group was significantly higher than those of the pneumonia and other infection groups (respectively, p=0.001, p=0.003). SAA levels were higher in the meningitis group than those of the pneumonia group (p=0.007). When patients were divided into two groups as invasive bacterial infection group and localised bacterial infection group; PCT levels were found significantly higher in the invasive bacterial infection group than those of the localised bacterial infection group. Also, percentage change of PCT at the 48th hour, 7 and 10 days was determined as significantly higher in the invasive bacterial infection group than that of the localised bacterial infection group.Conclusion: In this study, PCT seems to be a more valuable parameter in diagnosing invasive bacterial infections.Publication X-ray-evaluation(Aves Yayincilik, Ibrahim Kara, 2008-03-01) Hacımustafaoğlu, Mustafa; HACIMUSTAFAOĞLU, MUSTAFA KEMAL; Çelebi, Solmaz; ÇELEBİ, SOLMAZ; Yazıcı, Zeynep; YAZICI, ZEYNEP; Tıp Fakültesi; Radyoloji Ana Bilim Dalı; 0000-0003-4646-660X; AAI-2303-2021Publication Evaluation of micafungin use in children(Ankara Microbiology, 2020-01-01) Hacimustafaoglu, Mustafa; Yeşil, Edanur; YEŞİL, EDANUR; Çelebi, Solmaz; ÇELEBİ, SOLMAZ; Sezgin Evim, Melike; SEZGİN EVİM, MELİKE; Özer, Arife; Turan, Cansu; TURAN, CANSU; Timur, Demet; TİMUR, DEMET; Çakır, Salih Cağrı; ÇAKIR, SALİH ÇAĞRI; Bülbül, Beyhan; BÜLBÜL, BEYHAN; Ener, Beyza; ENER, BEYZA; Güneş, Adalet Meral; MERAL GÜNEŞ, ADALET; Koksal, Nilgun; Özkan, Hilal; ÖZKAN, HİLAL; Sevinir, Betul; SEVİNİR, BETÜL BERRİN; Düzcan Kilimci, Duygu; Tıp Fakültesi; Pediatri Onkoloji Ana Bilim Dalı; 0000-0002-8926-9959; 0000-0003-3146-6391; 0000-0001-5761-4757; 0000-0002-5720-1212; 0000-0002-3232-7652; 0000-0003-4646-660X; AAG-8523-2021; AEZ-2469-2022; GSO-3630-2022; AAH-1570-2021; HJZ-4508-2023; AAE-6201-2021; AAG-8393-2021; JCD-9679-2023Micafungin is recommended especially in patients with liver and kidney failure and in the presence of other side effects due to antifungals apart from its known priority indications such as invasive candidiasis. The aim of this study was to evaluate the children who have received micafungin treatment. In the study, 125 children who were hospitalized in the pediatric wards and intensive care units of our hospital and had used micafungin between November 2016 and January 2019 were analyzed retrospectively. Clinical data, micafungin indication, blood values on the first and fourth days of the treatment, side effects of the drug and efficacy were evaluated. Sixty percent (75/125) of the patients were male and the mean age of all the patients were 58 +/- 67 (0-215, 30) months. Approximately half of the cases (48%) had malignancy and 13% of them were premature. Sixty-two percent (n= 37) of the malignencies were hematological (27 acute lymphocytic leukemia, nine acute myeloid leukemia, one myelodysplastic syndrome) and 38% (n= 23) were oncological (six neuroblastoma, four Hodgkin lymphoma, two Non-Hodgkin's lymphoma, five sarcomas, one hepatoblastoma, five others) malignencies. The major cause of hospitalization was sepsis (53%). The patients had several risk factors like immunosuppressive therapy (n= 68, 54%), neutropenia (n= 61, 49%), central venous catheter (n= 102, 82%), nasogastric tube (n= 63, 50%), endotracheal intubation tube (n= 49, 39%), urinary catheter (n= 14, 11%) and total parenteral nutrition (n= 81, 65%). Thirteen percent (n= 16) of the cases were post-operative patients. Candida species were cultivated in 97 clinical specimens (blood, endotracheal aspirate, sputum, urine, etc.) among 23 (18%) of the patients. Thirteen (10%) of the patients had candidemia and 62% of them were non-albicans strains. In all candidemias, strains were echinocandin susceptible, and blood cultures were negative within four days. When all the patients (n= 125) were evaluated, a significant decrease in C-reactive protein, an increase in sodium, and a decrease in alanine aminotransferase were observed on the fourth day of micafungin treatment (p< 0.05). A total of 39 (31%) patients underwent various antifungal treatments for median seven (1-60) days prior to micafungin treatment. Fourteen (36%) of these 39 patients, had elevated liver function tests (LFT), 10 (26%) of them had hypokalemia, and five (13%) of them had elevated renal function tests. Ten (26%) patients had antifungal-induced hypokalemia previously; and potassium levels were normalized after micafungin treatment (p= 0.0001). The patients for which micafungin treatment was chosen due to elevated liver function tests (n= 47, 38%), whether the antifungalinduced or not; alanine aminotransferase and aspartate aminotransferase levels were decreased after micafungin treatment (p= 0.0001 and p= 0.0001, respectively). Nineteen (15%) of the patients have died within the first 30 days of micafungin treatment and one of them had candidemia. No micafungin treatment related significant side effects were observed in any of the patients. Our study showed that micafungin could be a safe and effective option in pediatric cases including newborns with high liver and kidney function tests.Publication Frequency and safety of COVID-19 vaccination in children with multisystem inflammatory syndrome: A telephonic interview-based analysis(Zhejiang Univ Press, 2022-08-16) Aykaç, Kübra; Öztürk, Kübra; Demir, Osman Oğuz; Gümüş, Dilan Demir; Aslan, Sevgi; Cem, Ela; Çelebi, Miray Yılmaz; Karabacak, Mustafa Doğan; Alkan, Gülsüm; Aksoy, Fatma Dilşad; Yayla, Burcu Ceylan Cura; Kepenekli, Eda; Çelebi, Solmaz; Emiroğlu, Melike; Devrim, İlker; Cengiz, Ali Bülent; Ceyhan, Mehmet; Özsürekçi, Yasemin; AKSOY, FATMA DİLŞAD; ÇELEBİ, SOLMAZ; Tıp Fakültesi; Çocuk Enfeksiyon Hastalıkları Ana Bilim Dalı Hastalıklar; DUC-0213-2022; ENK-4130-2022Publication Clinical clues(Aves Yayincilik, Ibrahim Kara, 2012-09-01) Gurpinar, Arif; GÜRPINAR, ARİF NURİ; Yazici, Zeynep; YAZICI, ZEYNEP; Celebi, Solmaz; ÇELEBİ, SOLMAZ; Hacimustafaoglu, Mustafa; HACIMUSTAFAOĞLU, MUSTAFA KEMAL; Tıp Fakültesi; Çocuk Cerrahi Ana Bilim Dalı; 0000-0003-4646-660X; AAI-2303-2021Publication The diagnostic value of serum amyloid a in early-onset neonatal sepsis in premature infants(Medcom, 2021-01-01) Dorum, Bayram Ali; Özkan, Hilal; Çakır, Salih Çağrı; Köksal, Nilgün; Gözal, Zeynep; Çelebi, Solmaz; Hacımustafoğlu, Mustafa; Dorum, Bayram Ali; ÖZKAN, HİLAL; ÇAKIR, SALİH ÇAĞRI; Köksal, Nilgün; Gözal, Zeynep; ÇELEBİ, SOLMAZ; Hacımustafoğlu, Mustafa; Tıp Fakültesi; Çocuk Hastalıkları Ana Bilim Dalı; Neonatoloji Bilim Dalı; 0000-0002-2823-8454; 0000-0001-5761-4757; AAG-8451-2021; HJZ-4508-2023; A-5375-2017; AEZ-2469-2022; JLX-9286-2023; FFA-6764-2022; CRX-2793-2022; CSN-9445-2022Purpose: In this study, the aim was to determine the distinct effectiveness of serum amyloid A in the early stage of early-onset neonatal sepsis in premature infants. Methods: Preterm newborns hospitalised between 2014 and 2017 for suspected early-onset neonatal sepsis were included in this prospective study. Patients were evaluated according to clinical and laboratory findings at admission and at the 24th and 48th hours after admission. The serum amyloid A values of the patients with sepsis and a control group were compared, and the blood cultures were evaluated. Results: A total of 319 premature newborns were included in the study: 150 in the sepsis group and 169 in the control group. Their birth weight ranged between 590 g and 3000g and the gestational age was 24-36 weeks. The serum amyloid A values at admission were significantly higher in the cases diagnosed with sepsis compared to the control group. Conclusion: Serum amyloid A is a reliable diagnostic marker for the early onset of neonatal sepsis, and it has a higher sensitivity at symptom onset or in the first hours after birth in premature infants.Publication Risk factors and clinical outcomes of infections caused by acinetobacter spp. in children: Results of a 5 year study(Aves Yayincilik, Ibrahim Kara, 2010-03-01) Çelebi, Solmaz; ÇELEBİ, SOLMAZ; Hacımustafaoğlu, Mustafa; HACIMUSTAFAOĞLU, MUSTAFA KEMAL; Yüce, Necla; Karalı, Zuhal; KARALI, ZUHAL; Gül, Yahya; Çakır, Deniz; Gedikoğlu, Suna; Tıp Fakültesi; Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı; 0000-0003-4646-660X; 0000-0002-7056-0615; GQP-2135-2022Objective: The number of infections caused by microorganisms of the genus Acinetobacter has increased in recent years. The aim of this study was to evaluate the risk factors and clinical outcomes associated with multidrug resistant (MDR) Acinetobacter infections in children and to define the predisposing factors associated with Acinetobacter spp. infection related mortality.Material and Method: We conducted a case-control study between January 1, 2004 and December 31, 2008 at the Uludag University Pediatric Clinic. Multidrug resistance was defined as resistance to all antibiotics apart from colistin. All patients with MDR Acinetobacter spp. infections were compared to patients with non-MDR Acinetobacter spp. infections. Risk factors analyzed included prior antibiotic use, underlying diseases, invasive medical devices, and other demographic characteristics.Results: Acinetobacter spp. infections were diagnosed in 95 of the 8879 patients hospitalized in our center between January 1, 2004 and December 31, 2008 (overall incidence, 10.6 per 1,000 admissions). The mean age of patients was 62.1+ 61.2 months (15 days-18 years) and 56% were male. The prevalence of MDR isolates among Acinetobacter spp. was found to be 33.6%. In this study, risk factors for MDR Acinetobacter spp. infections included prolonged hospitalization and prolonged exposure to broad-spectrum antibiotics (p< 0.05). The mortality rate of Acinetobacter spp. infection was found to be 26.3%. Predisposing factors associated with mortality were pediatric intensive care unit stay, male gender, ventilator associated pneumonia, presence of immunodeficiency or renal disease, presence of mechanical ventilation and MDR Acinetobacter spp. infections (p< 0.05).Conclusion: In this study, the prevalence of multidrugresistant isolates among Acinetobacter spp. was 33.6 %. The mortality (50%) for patients in the MDR group was significantly higher than the mortality for patients in the non-MDR group (11%) (p< 0.05).